Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Todd Bosanac

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Bioorganic & Medicinal Chemistry Letters|February 27, 2009
Morpholine containing CB2 selective agonistsRenée Zindell, Doris Riether, Todd Bosanac, et al.
Brain : a Journal of Neurology|May 8, 2021
Pharmacological SARM1 inhibition protects axon structure and function in paclitaxel-induced peripheral neuropathyTodd Bosanac, Robert O Hughes, Thomas Engber, et al.
Arthritis Research & Therapy|January 27, 2018
Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupusSamantha A Chalmers, Jing Wen, Jessica Doerner, et al.
Scientific Reports|May 20, 2016
Therapeutic Blockade of Immune Complex-Mediated Glomerulonephritis by Highly Selective Inhibition of Bruton's Tyrosine KinaseSamantha A Chalmers, Jessica Doerner, Todd Bosanac, et al.
Bioorganic & Medicinal Chemistry Letters|September 21, 2017
Discovery and optimization of oxadiazole-based FLAP inhibitorsAlessandra Bartolozzi, Asitha Abeywardane, Todd Bosanac, et al.
Bioorganic & Medicinal Chemistry Letters|August 4, 2010
Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 2, optimization for blood pressure reduction in spontaneously hypertensive ratsJohn D Ginn, Todd Bosanac, Rhonda Chen, et al.
Clinical Immunology (Orlando, Fla.)|October 20, 2018
BTK inhibition ameliorates kidney disease in spontaneous lupus nephritisSamantha A Chalmers, Elizabeth Glynn, Sayra J Garcia, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 6, 2016
A Soluble Guanylate Cyclase Activator Inhibits the Progression of Diabetic Nephropathy in the ZSF1 RatCarine M Boustany-Kari, Paul C Harrison, Hongxing Chen, et al.
ACS Medicinal Chemistry Letters|December 18, 2014
Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidateChristian Harcken, Doris Riether, Pingrong Liu, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 12, 2022
The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and DiseaseGlenn A Reinhart, Paul C Harrison, Kathleen Lincoln, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Bioorganic & Medicinal Chemistry Letters|February 27, 2009
Morpholine containing CB2 selective agonistsRenée Zindell, Doris Riether, Todd Bosanac, et al.
Brain : a Journal of Neurology|May 8, 2021
Pharmacological SARM1 inhibition protects axon structure and function in paclitaxel-induced peripheral neuropathyTodd Bosanac, Robert O Hughes, Thomas Engber, et al.
Arthritis Research & Therapy|January 27, 2018
Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupusSamantha A Chalmers, Jing Wen, Jessica Doerner, et al.
Scientific Reports|May 20, 2016
Therapeutic Blockade of Immune Complex-Mediated Glomerulonephritis by Highly Selective Inhibition of Bruton's Tyrosine KinaseSamantha A Chalmers, Jessica Doerner, Todd Bosanac, et al.
Bioorganic & Medicinal Chemistry Letters|September 21, 2017
Discovery and optimization of oxadiazole-based FLAP inhibitorsAlessandra Bartolozzi, Asitha Abeywardane, Todd Bosanac, et al.
Bioorganic & Medicinal Chemistry Letters|August 4, 2010
Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 2, optimization for blood pressure reduction in spontaneously hypertensive ratsJohn D Ginn, Todd Bosanac, Rhonda Chen, et al.
Clinical Immunology (Orlando, Fla.)|October 20, 2018
BTK inhibition ameliorates kidney disease in spontaneous lupus nephritisSamantha A Chalmers, Elizabeth Glynn, Sayra J Garcia, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 6, 2016
A Soluble Guanylate Cyclase Activator Inhibits the Progression of Diabetic Nephropathy in the ZSF1 RatCarine M Boustany-Kari, Paul C Harrison, Hongxing Chen, et al.
ACS Medicinal Chemistry Letters|December 18, 2014
Optimization of drug-like properties of nonsteroidal glucocorticoid mimetics and identification of a clinical candidateChristian Harcken, Doris Riether, Pingrong Liu, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 12, 2022
The Novel, Clinical-Stage Soluble Guanylate Cyclase Activator BI 685509 Protects from Disease Progression in Models of Renal Injury and DiseaseGlenn A Reinhart, Paul C Harrison, Kathleen Lincoln, et al.
Pageof 3